The global healthcare sector continues to attract significant interest from private equity firms seeking opportunities in specialized medical businesses. Apollo Global Management is reportedly exploring a potential acquisition of Johnson & Johnson’s orthopedics division, DePuy Synthes, in a deal that could approach $20 billion in value.

The potential transaction reflects a broader trend of healthcare companies reviewing portfolios and separating non-core assets to improve strategic focus. For investors, the discussions highlight the ongoing demand for established medical technology businesses with global operations and recurring demand drivers.

Private Equity Expands Healthcare Focus Through Major Asset Deals

Apollo Global Management, one of the world’s largest alternative asset managers, is reportedly in discussions to acquire DePuy Synthes, Johnson & Johnson’s orthopedic devices business. According to reports, an agreement could potentially be reached within several weeks, although the final structure of any transaction remains uncertain.

Johnson & Johnson is also considering alternatives, including spinning off the unit into a separate publicly traded company. The division has reportedly attracted interest from multiple private equity firms, reflecting strong investor appetite for healthcare assets that provide exposure to long-term demographic trends.

Orthopedics remains an important segment within medical technology, supported by aging populations, increasing demand for joint replacement procedures and continued innovation in surgical technologies.

Johnson & Johnson Continues Portfolio Restructuring Strategy

The potential sale of DePuy Synthes aligns with Johnson & Johnson’s broader strategy of refining its business structure. The company has previously taken steps to separate businesses and concentrate resources on higher-growth healthcare areas, including pharmaceuticals and medical innovation.

Strategic portfolio adjustments allow large healthcare companies to unlock value from mature divisions while providing specialized businesses with independent growth strategies. A transaction involving DePuy Synthes could represent one of the largest healthcare-related private equity deals in recent years.

However, any potential agreement would require negotiations over valuation, regulatory considerations and the long-term operational structure of the business.

Healthcare Deal Activity Remains Strong Despite Market Uncertainty

The reported interest in DePuy Synthes comes as private equity firms continue to seek opportunities in healthcare despite higher financing costs and a more selective investment environment. Medical technology companies with established brands, global distribution networks and predictable demand have remained attractive targets.

For Apollo, acquiring a major orthopedic business would strengthen its healthcare portfolio and provide exposure to a sector supported by structural growth trends. For Johnson & Johnson, a potential transaction could provide additional flexibility in allocating capital toward strategic priorities.

Market participants will continue monitoring whether Apollo and Johnson & Johnson move toward a definitive agreement, whether other bidders emerge and how the transaction could reshape competition in the global orthopedic devices market. The outcome may also provide insight into the broader appetite for large-scale healthcare deals as investors balance growth opportunities with economic uncertainty.